8 May, 2020
Our CEO, Dr Tim Oldham recently sat down with Stuart Roberts of Pitt Street research to talk about AdAlta’s growth strategy and upcoming Phase 1 clinical trials of lead candidate, AD-214.
In the interview, Dr Oldham discusses:
• The origination of i-bodies and how AdAlta is developing drugs for difficult to drug targets
• The benefits and flexibility of AdAlta’s i-body platform
• How existing treatments for Idiopathic Pulmonary Fibrosis (IPF) only modestly improve disease progression but do not reverse the condition
• How AdAlta is the first company to use the CXCR4 axis to attack fibrosis
• The significance of AdAlta’s upcoming Phase 1 trials for AD-214 which are due to commence in mid-2020, with IPF patients to be included from 2021
• How AdAlta is targeting multiple disease indicationsbeyond IPF
To view the interview, click here.
We look forward to updating you on our progress again soon.
Kind regards,
The AdAlta investor relations team
